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Executive Summary
Current trends in veterinary medicine indicate the potential need for several new services within
the VTH.  Based on focus groups and practitioner surveys conducted in late 1998 and early 1999,
potential new services could include oncology, overnight emergency, behavior medicine,
dentistry, equine sports medicine and exotic animal medicine.  Of these, an oncology service is
currently being considered based on internal staff recommendations coupled with survey and
focus group information supporting demand for the service.  Different from past new services, the
oncology service was also earmarked to undergo a formal market study to determine the full
potential of the opportunity and to more clearly establish the goals and objectives within the
service.
With that in mind, the objective of this study was to evaluate the market opportunity for
expanding the Veterinary Teaching Hospital services to include an oncology service.
The approach employed for the Oncology Market Study involved a forecasting process to assess
the market opportunity by using a variety of tools and data sources. This process built on a
summary of existing data as well as revised assumptions over time to include new data and
experience collected along the way.
Three key components of the study were identified: geographic market determination, demand
factors and supply factors. Market determination set the stage for focused marketing efforts and
outlines expectations for future growth as well as establishes the physical parameters for
measuring demand and supply.  Demand factors provided the basis for caseload estimates and
revenue projections. Supply factors were used to modify the opportunity by incorporating pricing
strategies and competitive effects.
Based on historical referral data, we determined Michigan State University’s primary market area
to be within a 150-mile radius of East Lansing, Michigan.  Specific geographic markets were then
defined based on primary population densities and metro area groupings within that radius.  Nineii
key market areas were identified through this process:  1) Detroit Metro/Southeastern Michigan,
2) Tri-City/Thumb, 3) Mid-Michigan, 4) Southwestern Michigan, 5) Western Michigan, 6) Upper
Lower Peninsula, 7) Tip of the Lower Peninsula, 8) Indiana and 9) Ohio.  Of these, the Detroit
Metro Area, Indiana and Ohio represent the largest initial opportunity for a new oncology service
located at MSU.
Caseload estimates were derived from projections of market area household population and pet
ownership statistics.  Three separate methods were used to develop a confident range of
expectations for MSU’s caseload:  1) cancer incidence and treatment rates, 2) minimum market
coverage expectations and 3) direct relationship comparison to a successful oncology service,
Colorado State University. Although the study caseload estimates varied depending upon method
used, the projections were consistent in their range.  In fact, the three private oncology services in
Southeastern Michigan have experienced as much as four to six week back logs in new case
admittance due to the overwhelming demand for oncology services in Michigan.  Based on
projections from these methods, we were able to develop a conservative estimate of potential
annual new malignancies for MSU of between 1,500 and 2,000 cases.
To develop revenue projections, we conducted surveys of seven other veterinary teaching hospital
oncology services.  From them, we obtained pricing strategies and revenue figures for major
oncology procedures.   Additionally, we polled private-practice services within the MSU market
area for their general pricing strategies and overall treatment revenue.  With this information, we
were able to create a conservative estimate of the average case revenue potential for the MSU
oncology service of $1,200 per case by choosing a reasonable mid-range from the reported
strategies.
Therefore, based on the estimates and projections made here, Michigan State University can
expect an annual total gross revenue for a fully-developed and successful new oncology service
of between $1.8M and $2.4M.  Initial marketing efforts should be focused on securing a client
base from the Southeast Michigan, Ohio and Indiana market areas.2
Introduction:
As demand for services continues to grow within the veterinary medical field, the Veterinary
Teaching Hospital (VTH) must expand its services to meet those demands.  Past methods for
determination of which services to expand have been somewhat arbitrary.  Oftentimes, new
service development has been driven not from demand within the medical community or the
animal-owning public, but rather by the immediate availability of resources or faculty interests.
These methods can often be contrary to efficient resource management and may result in
suboptimization of opportunities.
Current trends in veterinary medicine indicate the potential need for several new services within
the VTH.  Based on focus groups and practitioner surveys conducted in late 1998 and early 1999,
potential new services could include oncology, overnight emergency, behavior medicine,
dentistry, equine sports medicine and exotic animal medicine.
Of these, an oncology service is currently being considered based on internal staff
recommendations coupled with survey and focus group information supporting demand for the
service.  Different from past new services, the oncology service is also undergoing a formal
market opportunity study to determine the full potential of the opportunity and to more clearly
establish the goals and objectives within the service.  To fully understand the parameters of the
opportunity, a study must investigate the source of revenue and quantify it from both a
geographic and absolute caseload basis.  Assumptions must also be made on competitive impact
and referral base acceptance.  With that in mind, the objective of this study is to evaluate the
market opportunity for expanding the Veterinary Teaching Hospital services to include an
oncology service.3
 The potential opportunity is clearly identified both in revenue and caseload.  It is also a tool in
the next steps involving marketing plans and staffing procurement as the project moves forward.
Materials and Methods:
The approach recommended for the Oncology Market Study involves developing a forecasting
process to assess the market opportunity by using a variety of tools and data sources, including
conceptualization schemes, models, and other specialized analytical techniques. This process
builds on a summary of existing data sources as well as revised assumptions over time to include
new data and experience collected during the process.  The emphasis on continual learning about
the nature of the market opportunity leads to refined forecasts.  The general process with which
we proposed identifying the market opportunity for a new oncology service in the VTH is taken
from Thomas
1 and is outlined below.
Table 1 Market Opportunity Forecasting Process
1.  Diagnose and Conceptualize Key Market Factors:  Through a study of market opportunity for
the new service, identify and conceptually define the major factors (key variables and
stakeholders) in the new service situation hypothesized to influence demand.
2.  Formulate Spreadsheet and Submodels of Major Factors:  Using the identified factors to
estimate market size, growth and penetration, formulate spreadsheet and other submodels to
guide data collection.
3.  Collect Data on Key Variables:  Collect data for the various models to develop estimates of the
trends or expected directions on the major factors and their interactions over the new service
planning horizon.
4.  Analyze Data and Segment Market:  Analyze the data collected, with emphasis on the
segmentation structure of the market and possible alternative concepts for segments.
5.  Develop Enhanced New Service Scenarios:  Focusing on a selected segment, create a new
service scenario of base case and alternative futures from the trends and assumptions about the
effects of major factors on the new service.
6.  Estimate Market Potential and Penetration:  In the context of the new service scenario, use
the spreadsheet model to develop estimates of market potential and penetration.
7.  Continually Update Models and Estimates:  Incorporate new data and experience into the new
service models and scenarios over the cycle of service development and continually update
market opportunity forecasts.4
Multiple sources of information were utilized to identify three key components of the oncology
market opportunity study.  The three key components include: demand factors, supply factors and
geographic market determination.  Any product or service can be developed, measured and
tracked based on these factors.  Market determination sets the stage for focused marketing efforts
and outlines expectations for future growth as well as establishing the physical parameters for
measuring demand and supply.  Demand will provide the basis for caseload estimates and
revenue projections. Supply will modify the opportunity by incorporating pricing and competitive
effects.
Geographic Market Determination
Based on historical referral data, we determined Michigan State University’s primary market area
to be within an 150 mile radius of East Lansing, MI. (see Figure 1)  Once the primary market area
was established, we set about identifying smaller geographic markets defined by population
densities and metro area groupings.  These market areas were then broken down further into zip
code market groups in order to allow more detailed analysis of both population and revenue data.
2
(Figure 2)  Once we had identified all of the salient markets down to the zip code level, we could
then recombine markets into key marketing areas based upon definitive population centers.  This
would allow us to measure and forecast all projections for the oncology service. (Figure 3)  The
final purpose of determining key market areas is to be able to develop focused marketing efforts





Figure 1 MSU VTH: PRIMARY MARKET AREA8
Determining Demand Factors
Demand estimates for oncology services in this study were based primarily on the populations of
potential patients (dogs, cats and horses) and the cancer incidence rates associated with those
populations.  Initial pet population estimates were developed through identification of a total
number of households within the general marketing area encompassed by a 150-mile radius of
Michigan State University.  Household data were obtained from U.S. Census projections for year
2000
3.  Once total households were determined, estimates of canine, feline and equine pet
population were calculated using AVMA data estimates for the number of pets per household.
4
(see table 2)
Table 2  Number of pets per household calculations
Species % Households with Pets Avg. # of
Pets/household
MI OH IN All Regions Combined
Dogs 30.2 30.4 33.6 1.69
Cats 24.6 26.8 26.0 2.19
Horses 1.3 1.3 1.3 2.67
Source: AVMA 1997 U.S. Pet Ownership & Demographics Sourcebook, pp. 10,16,27
In addition to determining the total number of pets in our market area, we needed to apply a
cancer incidence rate to the numbers to determine the potential cancer pet population.  Cancer
incidence rates are not widely published due to the difficulty of truly quantifying the actual pet
population in the United States.  There are, however, several different projections and
assumptions being used by researchers at this time.  The most recent, and seemingly well
founded, projections come from Dorn and Priester
5.  Their estimates are based on an exhaustive
search of previous publications and research in conjunction with data analyzed from the National
Cancer Institute’s Veterinary Medical Data Base (VMDB), the California Animal Neoplasm
Registry (CANR) and the Tulsa Registry of Canine and Feline Neoplasms.  Based on their
research, they have determined cancer incidence rates for most of the major veterinary species.
For our purposes, we will use their data for dogs, cats and horses.  (see Table 3)9
Table 3 Estimated Rate of Malignancy/100,000/year




Source: Dorn and Priester, Veterinary Cancer Medicine, Theilen & Madewell (eds.), 1987, p37
Another key factor in determining demand is interest levels for the service among the key users,
in this case, referring veterinarians.  To determine the overall interest of referring veterinarians in
the idea of an oncology service at MSU, we conducted telephone interviews with many of MSU’s
top referral hospitals (based on revenue contribution).  Due to the difficulty in procuring lengthy
interview appointments, questions were limited to 3-4 key areas of interest.  These included:
1.)  Do you see a VTH Oncology Service as a positive move by MSU?
2.)  Can you see your practice referring to MSU Oncology?
3.)  Where do you refer oncology cases to now?
4.)  Do you have any “wish list” suggestions for the new service?
In all, practitioner reaction to the potential oncology service at MSU was highly positive.  Some
concerns were voiced as to the affordability of the services but most saw the service as a very
necessary addition to the VTH.  Verbatim comments are summarized, by practice location, in
Appendix A.
Determining Supply Factors and Revenue
Supply deals with where and how current oncology patients are getting care in the Michigan area.
There are currently only three board-certified oncologists registered for practice in Michigan.  All
three of them practice in southeastern Michigan at different hospitals and are exclusively small
animal.  As is the case now, the majority of Michigan animals in need of oncology treatments
must travel to the Detroit area for care.  Some cases are also being referred to the oncology
departments at University of Illinois and Purdue depending upon where they reside in the state.10
To determine where, historically, cancer cases originated within the MSU market area, we looked
to the Veterinary Medical DataBase
6 (VMDB) currently housed at Purdue University.  The
VMDB was originally set up in 1964 as a depository for diagnostic information from all of the
Veterinary Colleges in the U.S..  There are now only 6 CVMs actively supplying data to the
VMDB.  Michigan State has always been compliant and, thus, has a 36 year data stream from
which to glean information.  Due to the rapidly changing nature of cancer care and for the
purposes of this study, we have limited our analysis to an average of the last two years of
complete data as of the date of this report, in this case, calendar years 1998 and 1999.  This
information, in tandem with the projected cancer incidence rates, will allow us to determine a
cancer opportunity index by region.  This is calculated by dividing a region’s past cancer caseload
by its cancer incidence.  An index under 100 indicates a region which may provide an increased
caseload once a service at MSU in operational.  Conversely, an index over 100 indicates a region
which is actually over supplying cancer cases based on expected incidence.
Also under consideration in our supply model is pricing strategies.  We contacted the other CVMs
that have active oncology departments and surveyed for their pricing strategies. (See Appendix B)
Response was limited but the information gathered was helpful in developing estimated revenue
calculations for major oncology services.  In addition to the other CVMs, we also contacted two
of the three local oncology service providers to get a generalized idea of their pricing strategies as
well.  This information, in conjunction with direct comparisons with Colorado State’s current
caseload-to-population and revenue-to-caseload ratios, has given us a strong projection of future
revenue streams for the MSU Oncology Service.11
Results:
Population Estimates
Working within the 150-mile radius established earlier, we were able to estimate the total canine,
feline and equine populations to be as outlined in Table 4.
Table 4  Estimated Pet Populations
Region Dogs Cats Horses
MI       1,700,411     1,794,897   115,642
IN  (MI border)         170,326        170,794     10,411
OH (MI border)         151,571        173,155     10,240
Total       2,022,308     2,138,846   136,293
Source: AVMA 1997 U.S. Pet Ownership & Demographics Sourcebook, pp. 10,16,27,135
Source: Michigan Equine Monitoring System: Michigan Equine Survey, 1996
We used U.S. Census
7 data projected for year 2000 in the three states multiplied by the percent of
pet owning households and then applied a factor to estimate the average number of pets per
household.  Blending this information with the earlier key market area breakouts, we were able to
identify the general distribution of pets in the total Michigan State market area. (see Figure 4)
With the key market area divisions established, we were able to overlay MSU’s actual cancer
caseloads, by species, for 1998 and 1999.  Figures 5 through 8 represent canine, feline, equine
and total domestic animal cancer cases, respectively, by key MSU market area as percentages of
total for an average of the two years.
Caseload Determination
Once we had established a total pet population, we applied our incidence rates to determine the
total pet cancer incidence.  This gave us our “total pool” of potential patients.  From this pool we
factored in the effects of competitive service siphoning, failure by owners to pursue treatment and17
euthanasia rates.  Annual cancer population is established using the annual incidence factors
reported in Table 3 for the estimated pet population from Table 4.  (see Table 5)
Table 5  Estimated Annual Cancer Pet Populations
Dogs Cats Horses
Total Region 16,751 5,505 349
Source: AVMA 1997 U.S. Pet Ownership & Demographics Sourcebook, pp. 10,16,27,135
Source: Michigan Equine Monitoring System: Michigan Equine Survey, 1996
On an annual basis, there will be a total of over 22,600 potential new malignancies within the
MSU marketing area.  The breakout by key marketed area is represented in Figure 1.8 with the
Detroit Metro area accounting for nearly 45% of all cancer cases.  The literature tells us that 21%
of diagnosed cancer cases are euthanized
8  and, on average, 26% are skin tumors that may be
treated [surgically] by local practitioners.
9,10  If we assume that up to one third (33%) of owners
choose not to pursue referral treatment, we still have a potential referral pool of approximately
4,500 cases per year.  After conducting local interviews, we were able to ascertain that each of the
three private oncology practices average 400 new malignancy cases annually.  Therefore, MSU’s
potential pool of referral clients, according to this method of estimation, is still close to 3,300
cases per year.
To come to a conservative number based on the same projections we can focus on the percent of
population being serviced [Minimum Market Coverage].  If 47% (21% + 26%) of the total cancer
incidence are either euthanized or treated by their primary practitioners, that would leave a total
referral pool of 11,980 animals, annually.  Since we know that the three active oncology services
in Michigan are treating approximately 1,200 of these animals, annually, we know that just over
10% are being cared for currently.  If we made a modest assumption that, with the opening of
MSU’s oncology service, 25% of these animals would receive treatment, then MSU’s portion of18
the annual caseload would come to nearly 1,800 cases.  [11,980 * 0.25 = 2,995 less 1,200 to the
private oncology services]
Another means of determining caseload projections is to compare Colorado State University’s
market area pet population and the ratio of pet owning households-to-caseload to Michigan
State’s projected pet populations.
11  Using the previous calculations for determining pet
populations, we find that MSU’s market area pet population is projected at 2½ times larger than
that of CSU within a 150 mile radius of each institution. (see Table 6)
Table 6  Comparative Market Area Pet Populations
Dogs Cats Horses
MSU 2,022,308 2,138,846 136,293
CSU 827,475 824,622 96,075
Source: AVMA 1997 U.S. Pet Ownership & Demographics Sourcebook, pp. 10,16,27,135
Source: Michigan Equine Monitoring System: Michigan Equine Survey, 1996
We know from discussions with staff at CSU that their caseload of new malignancies is between
1,100 and 1,200 cases per year.  We also know that they also have three board certified
oncologists in private practice within 150 miles of the VTH.  On average, only 50% CSU’s
caseload is generated by households within Colorado.  Applying this to the surrounding
household population, we determined that CSU’s indigenous caseload is generated from
approximately 0.047% of the households within their market area.  Applying the same numbers to
MSU’s household population base, we could expect our new malignancy caseload to be
approximately 1,833 cases annually. . (see Table 7)
Table 7  Indigenous Caseload Calculations




CSU 0.047% 1,285,119 600
MSU 0.047% 3,925,634 1,833
Source:  United States Census Bureau Website: http://www.census.gov/datamap/www/19
Using this and the previous estimate methods, MSU’s potential oncology caseload can be
expected to be between 1,800 and 3,300 cases annually.
We also compared the median household incomes (HHI) and cost of living indices (COLI)
between Colorado and Michigan to insure that extrapolations could be made without the need for
modification calculations.  The median HHI for Colorado in 1998 was $46,599, which indexed at
119 to the total U.S. median and ranked the state as the 6
th highest in the nation.  Michigan’s
median HHI in 1998 was $41,821 with an index of 108 to the total U.S. and a ranking of 13
th in
the nation.
12  The COLI of each state was very comparable.  When compared to the U.S. average,
Michigan had an average cost of living index of 109 and Colorado was slightly lower at an
average of 105.
13  The two largest cities in each state, Detroit and Denver, indexed at 113 and
109, respectively.  With the similar COLI and HHI of Colorado and Michigan, we feel the
comparison of caseload to population is valid for future revenue calculations.
Projected Revenue Determination
For the purposes of this analysis on revenue potential, we will use a conservative caseload range
of  1,500 to 2,000 new MSU malignancies per year.  In order to accurately project the annual
revenue for the MSU oncology service, we must first develop an average revenue calculation per
case.  This has been done through a combination of pricing strategy surveys with other veterinary
college oncology services as well as market area surveys with Michigan private oncology service
providers.  An average revenue per case must take into consideration all aspects of oncological
services to include case work-ups, chemotherapy, radiation therapy and palliative therapy to name
a few.  This analysis was conducted with the understanding that many variables go into
determining the costs associated with any and all of the above treatment regimens.  We must,
however, come to an acceptable average per case to project revenue for MSU’s service.20
Among the responding veterinary colleges, the following averages were determined:
Work-ups $100  to  $150
Chemotherapy series $500  to  $1,500
Radiation series $1,000  to  $3,500
Brachytherapy $400 to  $1,000
Anesthesia (per series) $500  to  $700
Among the private practitioners in Michigan, the following averages were developed:
Work-ups $250  to  $400
Chemotherapy series (all inclusive) $1,000  to  $3,000
Radiation series(all inclusive) $2,850  to  $3,900
With this information, we were able to create a conservative estimate of the average case revenue
potential for the MSU oncology service of $1,200 per case by choosing a reasonable mid-range
from the reported strategies.  The upper and lower total revenue estimates, based on our previous
caseload assumptions, are illustrated in Table 8.  It should also be noted, at this time, that the
definition of a case for our caseload calculations is treated as a complete series or treatment
program for an individual animal and not each individual visit during a program.




Revenue per case Total Estimated Annual Revenue
Lower End 1,500 $1,200 $1,800,000
Upper End 2,000 $1,200 $2,400,000
Average 1,750 $1,200 $2,100,000
Source: AVMA 1997 U.S. Pet Ownership & Demographics Sourcebook, pp. 10,16,27,135
Source: Michigan Equine Monitoring System: Michigan Equine Survey, 1996
Regional Expectations
The majority of Michigan State University’s past VTH revenue has come from the mid-Michigan
region. (see Figure 9)  As has been indicated earlier, the majority of cancer cases are expected to22
originate out of the Detroit Metro region.  This is a fact we must keep in mind as we move toward
marketing the new VTH service.  On a percent per key market area basis, we can plot our past
total VTH revenue against past cancer cases versus future cancer cases to determine which
markets are over- or under-developed. (see Figure 10)  What this figure indicates is that the mid-
Michigan region is already highly over-developed in relation to the future opportunity while the
Detroit Metro region as well as Ohio and Indiana are all very under-developed.  These findings
will assist us, as we begin to develop our marketing plans, in knowing how to focus our resources
for optimal return.
Figure 10 Percent Breakouts by Market Area:  Comparison of  Total Past
VTH Revenue v. Past Cancer Cases v. Future Cancer Incidence
Discussion:
Although the study caseload estimates varied depending upon method used, the projections are
reasonable in their range.  In fact, the three private oncology services in Southeastern Michigan
have experienced as much as four to six week back logs in new case admittance due to the





































Past VTH Revenue Past Cancer Cases Cancer Incidence23
statewide have indicated that, in many cases, pet owners may often forego prolonged cancer
treatment on older animals if they would be required to drive more than three hours to get to the
service (i.e., Metro Detroit hospitals).  These animals may be converted into cases for a more
centrally located service such as Michigan State.
Caseload estimates used for revenue projections were less (at the low end) than in any of the
projection methods.  Utilizing percentage breakouts derived from the literature, we projected a
healthy 3,300-case/yr. estimate. Another method, the minimum market coverage method, gave us
a more conservative 1,800 cases/yr.  Finally, a direct comparison to Colorado State’s in-state
service puts estimates at 1,833 cases per year.  In our calculations, however, we used 1,500 new
cases per year as a low end and still project revenue of $1.8M per year.  At the top end, we used
2,000 new cases per year generating in the neighborhood of $2.4M annually.
Market Opportunity
The potential opportunity involved with a new oncology service at MSU is attractive.  To
optimize that opportunity MSU must allocate its resources and efforts in markets which will yield
the greatest return.  In order to prioritize market areas, we calculated development indices based
on comparisons between past cancer cases and expected future cancer incidence.  Key market
areas were segmented into three primary opportunity categories.  Markets in the ‘Growth &
Opportunity’ category represent those, based on our indices, which are under developed and
provide the greatest potential increase for caseload at MSU.  Of our key market areas, the Detroit
Metro area, Ohio and Indiana offer the greatest short-term opportunity.  The Tri-City/Thumb area
and Western Michigan also show growth potential. This is especially true for Western Michigan
due to MSU’s prime geographic location along any travel path to the Detroit area oncology
services.24
Based on interviews with oncology service providers in the Detroit Metro area, we find that there
is a real backlog of clients waiting to begin treatments.  The current service in Michigan are also
heavily chemotherapy oriented with some augmenting low-dose radiation capabilities.  A new
oncology service located at MSU will be able to dovetail with these services offering alternative
high-dose radiation capabilities and new technologies as well as affording much needed caseload
overflow relief.  In this sense, the new MSU service can be viewed more as complementary than
directly competitive.
The ‘Maintenance’ category includes markets that are currently over developed and should not
require additional resources beyond what is currently being employed.  It is important to note that
Maintenance does not mean to imply neglect.  The Maintenance markets are often the ‘bread and
butter’ of any service or business and should be carefully monitored to insure constant revenue
streams.   It is not surprising that the Mid-Michigan area falls into this category.  Due to its close
proximity to MSU, this area has a cancer opportunity index of 662 and currently accounts for
almost 35% of the Veterinary Teaching Hospital’s total revenue.  The other market area,
Southwestern Michigan indexes just slightly over 100 and does not show increased opportunity at
this time.  This may be partially due to the siphoning effect of oncology services at the University
of Illinois and Purdue University drawing from the potential caseload pool.
The final market category is referred to as ‘Low Priority’.  These markets, also not to be simply
neglected, are however, small enough to play a minor roll in any large-scale marketing efforts.
Low Priority markets are often those, which, due to either distance from the service or
demographic/economic make up, account for less than 10% of current revenue. In this case,
distance and low population densities seem to be the key factors at work in the results accounting
for the designation of the Upper Lower Peninsula and Tip of the Lower Peninsula areas as Low
Priority.  Table 9 summarizes our findings.25







(over developed) Low Priority
Ohio 5.1
Indiana 8.5
Detroit Metro Area 47.6




Upper Lower Peninsula 81.2
Northern Tip of  Lower Peninsula 2.5
Summary:
Dr. William R. Pritchard, during an address to the American Veterinary Medical Association
challenged: “If every U.S. veterinary college would identify even one strength based on unique
resources or strengths, and commit the college to achieving the status of a world-class center on
that subject, veterinary colleges as a whole would soon make a major impact on science and
human medicine and would contribute much more to animal production and health.”  He went on
to say, “A center of world-class quality would command research support from traditional
funding sources and private donors; would attract outstanding faculty, professional and graduate
students; and would be a superb learning environment for all students.”
14  Michigan State
University should continue to pursue the establishment of an oncology service for the VTH in
earnest.  If minimum revenue projections materialize, staff funding should not be seen as a
concern.  Given the lack of any truly ‘world-class’ cancer centers in the Midwestern United States
or Canada, perhaps MSU should set its sites high as they move forward and assume responsibility
as a leader in the oncology field.26
As the project moves forward, consideration should be given to focusing on the key market areas
for early advertising and fund raising.  A sense of anticipation should be cultivated in the Growth
& Opportunity markets, which will culminate in the ultimate opening of the oncology service.
Formal marketing plan development should be included in the ongoing phases of public relations
and fund raising to insure proper focus and a smooth transition once the service is activated.  In
all, an oncology service at Michigan State University is medically necessary, expected by
referring practitioners and potentially highly profitable.  It is the recommendation of this study
that MSU continues pursuit of this service.27
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APPENDIX A
Telephone Interview Questions:
1.)  Do you see a VTH Oncology Service as a positive move by MSU?
2.)  Can you see your practice referring to MSU Oncology?
3.)  Where do you refer oncology cases to now?
4.)  Do you have any “wish list” suggestions for the new service?
Verbatim Comments:
Few patients will take advantage
Grand Rapids Most can’t afford it
Not for it! Would not be using this service
Maybe one case per year seen
Metamora Most can’t afford
Very interested!
Saginaw Now referrals go to OVRS
Would use!
Sure!
Okemos Now send to Detroit
Need oncologist for first investigation
May take over after first treatment
Yes, need!
Eagle Referral to Detroit now
More people are willing to pursue
Most clientele can’t afford
Flint May have cases in future if service is open
Would use
Bay City Now referring to Detroit
See many patients but lower income
Will use! Have used Mostosky
Lansing Currently refer to Detroit or treat themselves
Need oncologists!
Kalamazoo Will use!
Have called U of I and P.U. and C.S.U. in past
Would use
Ypsilanti Would like consultations
Needs to be affordable
Will support if they have integrity and good
Madison Heights service– timely!
Critically important to have oncology at MSU!29
Would use
Saginaw Increased incidence within clinic – 1 per week consult
Oncology consult with histopath results would be valuable and
essential
Potential is there – very supportive
Rochester Have been referring to OVRS
Send to OVRS now and may continue for client’s convenience
They are for the service
Milford Will send to MSU
In favor
Grand Rapids Have referred to MVS and Dr. Beck
Getting more client interest
Yes!
Vicksburg Have done some chemotherapy
Have referred to Purdue and Detroit
Affluent clientele
Benefit to hospital
Livonia Now referring to OVRS and Dr. Beck
Will send/recommend to MSU
Absolutely!
Farmington We always start with MSU as referral option
Seeing increase in cancer diagnoses
Need quick turnaround – no long waits to get in
Need oncologist at MSU
Grayling Look for MSU to begin treatment and run consult
Don’t undercut Detroit prices
Good idea!
Midland Do refer out to OVRS
Don’t make us wait, and follow through
Very excited
Brighton Refer to OVRS
We see quite a few cancer patients now—we’ll keep you busy
Might use
Kalamazoo (Eq) Most horses have squamous cell carcinomas; easy surgery or
euthanasia
Sometimes more serious
Some cases will use
Bridgeport (Eq) Not overwhelming amount of cases (not even weekly)
75% of cancers seen are sarcoids or melanomas – cryotherapy
Would use
Ann Arbor Have referred to Dr. Beck or OVRS
Consultation will be helpful30
Not a bad idea
Howell Refer to Dr. Beck
Quick turnaround on consultation
Will probably send
Warren Use OVRS but they’re busy
See more client willingness to treat
Have some patients which need
Mt. Pleasant Would use
Don’t see much use
Centerville (Eq) Won’t send much to MSU
Would love it!
Metamora (SA/Eq) Need alternative to OVRS – too busy
Can see an increasing need in equine
Would see definite need
Fowlerville (SA/Eq) Couple cases/yr for equine
Now SA goes to OVRS
Great idea!
St. Johns Do see a lot of cancer, but not successful in getting clients to
commit
Interested
Battle Creek Certain people will do it
Do radiation with Dr. Mostosky
None to Detroit
Terrific idea!
Traverse City Send to OVRS rarely
Have 2-3 cancers/wk
Good idea
So. Haven Referring to MSU and OVRS now
Definitely something we need
Howell Refer to OVRS
Increase in commitment
Very beneficial
So. Lyon (SA/Eq) Refer to OVRS
Equine is cost-benefit factor
May not use for treatment
So. Lyon (Eq) Majority sarcoid and melanoma
Cost/benefit prohibitiveAPPENDIX B
ONCOLOGY PRICING STRATEGIES:  VETERINARY TEACHING HOSPITALS
CVM #1: Midwest CVM #2: West CVM #3: South CVM #4: Midwest CVM #5: East CVM #6: West CVM #7: South
Staffing: FTE Veterinarians - Board Certified: 1 4 faculty;2.0FTE 2 IM diplomats 1 3 4.5 2
Staffing: FTE Veterinarians - Non-Board Certified: 6 3 residents
1 Onco Surgeon + 4 
Res + 2 Interns 0 5.5 0
Staffing: FTE Technicians: 5 4 staff; 3.5FTE 1 FT nurse 4 FT 5 8.5 3.5
Annual New Malignancy Case Load 1,200 n/a 780 500 1,100
Annual Revenue From Oncology Services $140,000 $300,000  $960,000 
~$2M   (~20% of total 
VTH) $798,443
Standard Oncology Examination $21.00 $70.00 IM appt. $60 $30.50  $55.00  $52.00 $140.00
Referral Oncology Examination $60.00 - $95.00 Same $59.00  $80.00  $52.00 $140.00
Weekly Recheck Examination $21.00 - $33.00 N/A $56, $42, $36 $22.00  $30.00  $21.00 $35.00
Three Week Recheck Examination $21.00 - $33.00 N/A $35.50  $30.00  $21.00 $35.00








Biopsy= $35-68 + 
Anesth.
Chemo Minor (butterfly) 
and recheck $42.00, 
$36.00
Consultation - In House $255.00 variable n/a $6.50 $28.00  $52.00 $20.00
Consultation - Telephone na N/A n/a $46.00  $25 - $50 $0.00
Fine Needle Aspirate $9.00 $35 (lab fee) $14.00 per mass $40.00 $39.00 $13.00
Cytology $14.00 $35 (lab fee) $18.00 $19.00 $29.00 $24.00 $17.00
Bone Marrow Aspirate $14.00 $45 (lab fee) $32  $37.00 $85.00 $22.00 $37.00
Histopathology $5.00 - $28.00 $60-75(path fee) $33  $43.00 $50.00 $33.00 $60  -  $90





Body mapping (map in 
medical record)=$30 
and up Biopsy $30 - $50
Chemosensitivity Assay na n/a n/a





administration = $26 Txt Plan Fee: $400
Radiation Therapy - per treatment na $95 $130.00  $88.00 $100.00
Radiation Therapy - per series na $950  $3,500 and up $1,800 - $2,700 $2,080 -$3,000 $1,320 - $1,760
$2,500 - $3,000 
inclusive
Radiation Therapy Consultation na N/A $100 - $200 $231.00 $140.00
I-131 Therapy $675.00 $550.00  $600.00  $1,450.00 $1,200.00
Cobalt Therapy Fee: na N/A $100.00
Brachytherapy na $415 $600-$1000
Anesthesia $10.00 - $27.00 $630/series $65, addl hr $15 $155 - $220 $44/hr included in fee
Oncology Boarding (if different From general Board) na reg hosp fees $18-$200 $20 - $25 $23.00 $40.00
Other
Boarding fees adjust to 
size and location of 
patient (i.e. ICU vs. the 
wards)
Palliative Therapy: 
$750